SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction

Journal of Infectious Diseases

Volumn 213, Issue 9, 2016, Pages 1419-1427

  Panigrahi, Soumya ^a   Freeman, Michael L ^a   Funderburg, Nicholas T ^c   Mudd, Joseph C ^d   Younes, Souheil A ^a   Sieg, Scott F ^a   Zidar, David A ^a   Paiardini, Mirko ^e   Villinger, Francois ^e   Calabrese, Leonard H ^a   Ransohoff, Richard M ^b   Jain, Mukesh K ^a   Lederman, Michael M ^a,f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

endothelial dysfunction; eNOS; immunohistochemistry; KLF2; LPS; oxLDL; SHIV; simvastatin; SIV

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD68 ANTIGEN; CD8 ANTIGEN; DNA 16S; ENDOTHELIAL NITRIC OXIDE SYNTHASE; KRUPPEL LIKE FACTOR 2; OXIDIZED LOW DENSITY LIPOPROTEIN; SIMVASTATIN; BACTERIAL DNA; KRUPPEL LIKE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; INFLAMMATORY CELL; LIPID OXIDATION; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; THORACIC AORTA; VASCULITIS; ANIMAL; CELL CULTURE; CYTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MICROBIOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA, THORACIC; CELLS, CULTURED; DNA, BACTERIAL; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HIV-1; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VASCULITIS;

EID: 84971510783     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv749     Document Type: Article

References (50)

1. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109:2698-704.
2. Stein JH, Hsue PY. Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA 2012; 308:405-6.
3. Triant VA. Epidemiology of coronary heart disease in patients with human immunodeficiency virus. Rev Cardiovasc Med 2014; 15(suppl 1):S1-8.
4. Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection. Thromb Res 2014; 133(suppl 1):S21-4.
5. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-41.
6. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115:161-7.
7. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-86.
8. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Natural SIV hosts: showing AIDS the door. Science 2012; 335:1188-93.
9. Estes JD, Harris LD, Klatt NR, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 2010; 6:e1001052.
10. Pandrea I, Cornell E, Wilson C, et al. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 2012; 120:1357-66.
11. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
12. Zidar DA, Juchnowski S, Ferrari B, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. J Acquir Immune Defic Syndr 2015; 69:154-60.
13. Naidu YM, Kestler HW III, Li Y, et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol 1988; 62:4691-6.
14. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999; 284:816-9.
15. Siddappa NB, Song R, Kramer VG, et al. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol 2009; 83: 1422-32.
16. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVAvaccine. Science 2001; 292:69-74.
17. Campos PF, Gilbert TM. DNA extraction from formalin-fixed material. Methods Mol Biol 2012; 840:81-5.
18. Imrit K, Goldfischer M, Wang J, et al. Identification of bacteria in formalin-fixed, paraffin-embedded heart valve tissue via 16S rRNA gene nucleotide sequencing. J Clin Microbiol 2006; 44:2609-11.
19. Wagstaff KM, Glover DJ, Tremethick DJ, Jans DA. Histone-mediated transduction as an efficient means for gene delivery. Mol Ther 2007; 15:721-31.
20. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31:632-43.
21. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res 2012; 129:301-8.
22. Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM 2003; 96:825-32.
23. Kolluru GK, Siamwala JH, Chatterjee S. eNOS phosphorylation in health and disease. Biochimie 2010; 92:1186-98.
24. Nayak L, Goduni L, Takami Y, et al. Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol 2013; 182:1696-704.
25. Atkins GB, Wang Y, Mahabeleshwar GH, et al. Hemizygous deficiency of Kruppel-like factor 2 augments experimental atherosclerosis. Circ Res 2008; 103:690-3.
26. Mahabeleshwar GH, Qureshi MA, Takami Y, Sharma N, Lingrel JB, Jain MK. A myeloid hypoxia-inducible factor 1α-Kruppel-like factor 2 pathway regulates gram-positive endotoxin-mediated sepsis. J Biol Chem 2012; 287:1448-57.
27. SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004; 199:1305-15.
28. Lin Z, Kumar A, SenBanerjee S, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 2005; 96:e48-57.
29. Lin Z, Hamik A, Jain R, Kumar A, Jain MK. Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation. Arterioscler Thromb Vasc Biol 2006; 26:1185-9.
30. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4:977-87.
31. Gordon SN, Klatt NR, Bosinger SE, et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007; 179:3026-34.
32. Das H, Kumar A, Lin Z, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A 2006; 103:6653-8.
33. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005; 112:720-6.
34. van Tits LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhoef AF. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: A crucial role for Kruppel-like factor 2. Atherosclerosis 2011; 214:345-9.
35. Palella FJ Jr, Delaney KM, Moorman AC, et al. HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
36. Detels R, Munoz A, McFarlane G, et al. Multicenter AIDS Cohort Study Investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280:1497-503.
37. Calza L, Manfredi R, Pocaterra D, Chiodo F. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect 2008; 57:16-32.
38. Knudsen A, Mathiasen AB,Worck RH, et al. Angiographic features and cardiovascular risk factors in human immunodeficiency virus-infected patients with firsttime acute coronary syndrome. Am J Cardiol 2013; 111:63-7.
39. Bozzette SA, Ake CF, Tam HK, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:338-41.
40. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
41. Miller CJ, Baker JV, Bormann AM, et al. Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One 2014; 9:e95061.
42. Nordell AD, McKenna M, Borges AH, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3:e000844.
43. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994; 76:301-14.
44. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-76.
45. Stein JH, Brown TT, Ribaudo HJ, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2013; 27:929-37.
46. Lebech AM, Kristoffersen US, Wiinberg N, et al. Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. Eur J Nucl Med Mol Imaging 2008; 35:2049-58.
47. Graham SM, Mwilu R, Liles WC. Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: A systematic review. Virulence 2013; 4:564-71.
48. Tuomisto TT, Lumivuori H, Kansanen E, et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res 2008; 78:175-84.
49. Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone MA Jr, Garcia-Cardena G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 2005; 280:26714-9.
50. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68:396-404.